These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20841376)

  • 1. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.
    Nath A; Zientek MA; Burke BJ; Jiang Y; Atkins WM
    Drug Metab Dispos; 2010 Dec; 38(12):2195-203. PubMed ID: 20841376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.
    Khojasteh SC; Prabhu S; Kenny JR; Halladay JS; Lu AY
    Eur J Drug Metab Pharmacokinet; 2011 Mar; 36(1):1-16. PubMed ID: 21336516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 networks in chemical space.
    Lee S; Kim D
    Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
    Yap CW; Xue Y; Li ZR; Chen YZ
    Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative index of substrate promiscuity.
    Nath A; Atkins WM
    Biochemistry; 2008 Jan; 47(1):157-66. PubMed ID: 18081310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
    Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
    Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.
    Marks BD; Smith RW; Braun HA; Goossens TA; Christenson M; Ozers MS; Lebakken CS; Trubetskoy OV
    Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):73-81. PubMed ID: 15090158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
    Lewis DF
    Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Fontana E; Dansette PM; Poli SM
    Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes.
    Xu F; Falck JR; Ortiz de Montellano PR; Kroetz DL
    J Pharmacol Exp Ther; 2004 Mar; 308(3):887-95. PubMed ID: 14634044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorometric high-throughput screening for inhibitors of cytochrome P450.
    Miller VP; Stresser DM; Blanchard AP; Turner S; Crespi CL
    Ann N Y Acad Sci; 2000; 919():26-32. PubMed ID: 11083094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WhichCyp: prediction of cytochromes P450 inhibition.
    Rostkowski M; Spjuth O; Rydberg P
    Bioinformatics; 2013 Aug; 29(16):2051-2. PubMed ID: 23740742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate modeling of cytochrome P450 3A4 inhibition.
    Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T
    Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards.
    Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
    Drug Metab Pharmacokinet; 2012; 27(5):520-9. PubMed ID: 22498647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of Machine Learning Techniques for Prediction of the Isoform Specificity of Cytochrome P450 Substrates.
    Xiong Y; Qiao Y; Kihara D; Zhang HY; Zhu X; Wei DQ
    Curr Drug Metab; 2019 May; 20(3):229-235. PubMed ID: 30338736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery.
    Gelboin HV; Krausz KW; Gonzalez FJ; Yang TJ
    Trends Pharmacol Sci; 1999 Nov; 20(11):432-8. PubMed ID: 10542439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.